[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-bladder-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-bladder-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100635114","acupuncture-and-exercise-for-ev-pembro-induced-peripheral-neuropathy-100635114",false,"NCT07548476","Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy","Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy (ACE)","ACE","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Diagnosed with pathologically proven advanced or metastatic urothelial cancer (mUC)\n* Planning to receive treatment with EV-Pembro or have received up to two cycles of EV-Pembro treatment with enrollment occurring prior to the start of the third cycle\n* Self-reported ability to walk for 6 minutes and\u002For 2 blocks\n* Deemed acceptable for exercise by their treating provider\n* Sedentary, currently engaging in less than or equal to 60 minutes of moderate or vigorous structured exercise\u002Fweek, as assessed by the Godin Leisure-Time Exercise Questionnaire\n* Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments\n* Eligible per verbally administered Physical Activity Readiness Questionnaire (PAR-Q+)\n* Referrals to physical therapy are allowed during the study if necessary; and\n* Participants taking any of medications listed below must be on a stable regimen, with no changes in the past three months. Use of these medications may continue while on study.\n* Duloxetine, amitriptyline, nortriptyline, gabapentin, and pregabalin\n\nExclusion Criteria:\n\n* History of peripheral neuropathy prior to EV-Pembro initiation\n* Patients with a pacemaker or other electronically charged medical device; or\n* Participate in more than 60 minutes of moderate or vigorous structured exercise\u002Fweek\n\nInvestigators will not include the following special populations:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers \\\u003C 18 years)\n* Pregnant women\n* Prisoners","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro).\n\nThe names of the two study groups in this research study are:\n\n* Acupuncture + Virtual Exercise (AVE)\n* Virtual Exercise Only (VE)",[27,28,29,30],"Metastatic Bladder Cancer","Peripheral Neuropathy","Advanced Urothelial Cancer","Metastatic Urothelial Cancer",[32,33,34],"Enfortumab Vedotin-Induced Neuropathy","Pembrolizumab-Induced Neuropathy","mUC","NOT_YET_RECRUITING","2026-04-28",{"date":38,"type":39},"2026-05-04","ACTUAL",{"date":41,"type":21},"2026-10-02",{"date":43,"type":21},"2027-03-02",{"name":45,"class":46},"Dana-Farber Cancer Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100526731","management-of-cisplatin-ineligible-patients-with-metastatic-bladder-cancer-and-the-role-of-geriatric-assessments-100526731","NCT06138561","Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments","Inclusion Criteria:\n\n* Age ≥65-years-old (study will limit total enrollment of patients between ages 65-70 to 20% of the total study population)\n* Unresectable or metastatic bladder cancer with histologically proven urothelial carcinoma. Any component of variant histology is allowed\n* Cisplatin-ineligible as determined by the subject's primary oncologist\n* Receiving treatment with chemotherapy (+\u002F- immunotherapy maintenance), enfortumab vedotin-pembrolizumab combination therapy or immunotherapy alone\n* Ability to understand and the willingness to sign a written informed consent document and to complete patient reported outcomes that will be in English or Spanish either alone or with assistance of study researcher or family\n\nExclusion Criteria:\n\n* Subjects who elect to not undergo cancer-directed therapy\n* Subjects obtaining their care outside of DFCI or DFCI affiliate sites\n* Advanced cognitive impairment or inability to complete surveys\n* Participants who are receiving any other investigational agents for this condition (if appropriate only).","65 Years",{"count":56,"type":21},180,"OBSERVATIONAL","The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.",[60,27,61,62],"Bladder Cancer","Unresectable Bladder Carcinoma","Urothelial Carcinoma",[60,27,61,62],"RECRUITING","2026-02-13",{"date":67,"type":39},"2026-02-17",{"date":69,"type":39},"2024-03-05",{"date":71,"type":21},"2028-01-01",{"name":45,"class":46}]